
Deep Bio is a South Korean company specializing in AI-driven cancer pathology diagnostics. They develop software solutions, branded as DeepDx®, that leverage deep learning to analyze tissue slides, assisting pathologists in diagnosing diseases like prostate and breast cancer with greater accuracy, sensitivity, and specificity. Their technology aims to address challenges such as pathologist shortages and diagnostic discordance by providing objective, reproducible metrics. The company has a suite of products including DeepDx® Prostate for various prostate biopsy analyses and DeepDx® Breast for resection and SLNB. They also offer the DeepDx® Viewer for slide analysis. Deep Bio emphasizes its technological innovation, evidenced by numerous publications, patents, and recognition, including a CES Innovation Award. Their solutions are designed to empower clinicians, optimize treatment decisions, and ultimately improve patient outcomes.

Deep Bio is a South Korean company specializing in AI-driven cancer pathology diagnostics. They develop software solutions, branded as DeepDx®, that leverage deep learning to analyze tissue slides, assisting pathologists in diagnosing diseases like prostate and breast cancer with greater accuracy, sensitivity, and specificity. Their technology aims to address challenges such as pathologist shortages and diagnostic discordance by providing objective, reproducible metrics. The company has a suite of products including DeepDx® Prostate for various prostate biopsy analyses and DeepDx® Breast for resection and SLNB. They also offer the DeepDx® Viewer for slide analysis. Deep Bio emphasizes its technological innovation, evidenced by numerous publications, patents, and recognition, including a CES Innovation Award. Their solutions are designed to empower clinicians, optimize treatment decisions, and ultimately improve patient outcomes.